Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10016


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining carboplatin, temozolomide, and filgrastim in treating patients who have newly diagnosed or recurrent high-grade glioma.

Study summary:

OBJECTIVES: - Determine the response rate in patients with newly diagnosed high-grade glioma treated with temozolomide, carboplatin, and filgrastim (G-CSF). - Determine the toxicity of this treatment regimen in these patients. - Determine the rate of tumor progression in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients are stratified according to disease category (glioblastoma multiforme vs anaplastic astrocytoma vs several other high-grade mixed gliomas). Patients receive carboplatin IV over 4 hours on days 1-2; oral temozolomide every 12 hours on days 1-5; and filgrastim (G-CSF) subcutaneously or IV daily starting no earlier than day 7 and continuing until blood counts recover. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 102-222 (17-37 per each of 6 strata) will be accrued for this study within 4 years.


DISEASE CHARACTERISTICS: - Histologically confirmed newly diagnosed glioblastoma multiforme or anaplastic astrocytoma - Residual tumor on postoperative MRI - Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: - Under 65 Performance status: - Karnofsky or Lansky 70-100% OR - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,000/mm^3 - Hemoglobin at least 8 g/dL (transfusion allowed) - Platelet count greater than 100,000/mm^3 Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGPT no greater than 3 times ULN Renal: - Age 5 years and under: Creatinine less than 1.2 mg/dL - Age over 5 to 10 years: Creatinine less than 1.5 mg/dL - Age over 10 to 15 years: Creatinine less than 1.8 mg/dL - Age over 15 years: Creatinine less than 2.4 mg/dL Cardiovascular: - No myocardial infarction within the past 6 months Other: - No other concurrent serious medical condition that would preclude study - Able to tolerate oral medications - No prior malignancy for which patient received prior chemotherapy or spinal irradiation - No history of severe allergic reaction to platinum-containing compounds - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 72 hours since prior filgrastim (G-CSF) Chemotherapy: - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - Concurrent steroids for tumor-related cerebral edema allowed - No concurrent corticosteroids for solely antiemetic purposes Radiotherapy: - No prior or concurrent radiotherapy Surgery: - Recovered from prior surgery - No concurrent surgery

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

Official Title:

Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, Both Newly-Diagnosed and Recurrent

Overall Status:


Study Phase:

Phase 2



Minimum Age:


Maximum Age:

64 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

New York University School of Medicine

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Jonathan L. Finlay, MB, ChB
Study Chair
New York University School of Medicine

Study Dates

Start Date:November 1997
Verification Date:August 2015
Last Changed Date:August 3, 2015
First Received Date:September 11, 2000

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Biological
Intervention Type:Drug
Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:New York University School of Medicine
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.